Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma

University of Southern California35 enrolled

Overview

The purpose of this study is first to establish what is the ideal dose of gemcitabine, a chemotherapy agent, when given in combination with radiation. In addition, the investigators want to determine the side effects and the effectiveness of this combination. The investigators will also study several markers to try to identify markers or tests that will predict which patients will benefit more from this treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Uterine Cervical Cancer

Interventions

GemcitabineDRUG

Gemcitabine weekly x 6 wks with concurrent external radiation

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with histologically confirmed bulky stage Ib or stage IIa cervical cancer. Bulky stage Ib disease is defined as tumor mass greater than 4 cms in diameter. * Cervical lesion which is measurable by physical examination. * No prior therapy for invasive cervical cancer. * GOG performance status 0-2 * Signed informed consent * Patients must have adequate: * Bone marrow function: absolute granulocyte count \> or = to 1500, platelet count \> 100,000. * Renal function: creatinine \< or = to 1.8 mg/dl * Hepatic function: bilirubin \< or = to 1.5 x normal, SGOT and alkaline phosphatase \< or = to 3 x normal Exclusion Criteria: * Patients with a history of prior malignancy, except adequately treated basal cell or squamous cell carcinoma of the skin, or other cancer for which the patient has been disease free for at least five years. * Pregnant or lactating women. Women of reproductive age may not participate unless they have agreed to use an effective method of birth control. * Patients with uncontrolled infection. * Patients who are HIV positive * Patients with psychiatric or social conditions that would interfere with consent or follow-up. * Patients with any other severe concurrent disease, which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Locations (1)

USC/Norris Comprehensive Cancer Center

Los Angeles, California, United States

Outcomes

Primary Outcomes

Toxicity (Number of Participants With Serious Adverse Events)

Summary of grade 3 or higher toxicities as per Common Toxicity Criteria version 2.0. Phase 1 and 2 Combined (N=35)

Time frame: Every 3 weeks from start of study until 30 days after the last dose of treatment

Secondary Outcomes

Best Overall Response of Either a Complete Response (CR) or Partial Response (PR)

Participants who complete the 6 weeks of chemotherapy and radiation or who experience dose limiting toxicity or who progress at any time prior to completion of the 6 weeks of chemotherapy and radiation will be evaluable for response. Complete response (CR): Complete disappearance of all measurable and evaluable disease. No new lesions. No disease related symptoms. No evidence of nonevaluable disease, including normalization of markers and other abnormal lab values. All measurable, evaluable, and nonevaluable lesions and sites must be assessed using the same technique as baseline. Partial response (PR): Applies only to patients with at least one measurable lesion. Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions. All measurable and evaluable lesions and sites must be assessed using the same techniques as baseline.

Time frame: Baseline to response (up to 24 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.